I-Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced its workforce by around 27% in conjunction with the pipeline ...

I-Mab has made a pipeline pivot, pausing work on an asset Sanofi bought into last year to focus on its play for the congested CLDN18.2 space.

China-based biotech company I-Mab said on Friday that AbbVie has terminated a 2020 deal to co-develop and market I-Mab's lead cancer drug candidate lemzoparlimab.

I-Mab (IMAB) stock in focus as the company agrees to buy Bridge Health to secure rights for CLDN18.2 antibody used in its cancer drug, givastomig. Read more here.

JACKSON, Miss. (WLOX) - At the 2025 Mississippi Association of Broadcasters (MAB) awards Saturday night in Jackson, WLOX took home 31 Excellence in Broadcasting awards, 11 of those being first place.

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 ...

Innovative bioprocessing technologies are needed to make monoclonal antibody (mAb) production cheaper, according to new research, which suggests lowering the cost of goods (COGs) for mAb-based ...